Technical Analysis for CADL - Candel Therapeutics, Inc.

Grade Last Price % Change Price Change
D 6.85 2.54% 0.17
CADL closed up 6.88 percent on Tuesday, January 18, 2022, on 1.52 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Flat
Historical CADL trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 2.54%
NR7 Range Contraction 2.54%
Wide Bands Range Expansion 2.54%
Oversold Stochastic Weakness 2.54%
Inside Day Range Contraction 9.60%
Wide Bands Range Expansion 9.60%
Oversold Stochastic Weakness 9.60%
MACD Bearish Signal Line Cross Bearish 6.20%
Stochastic Reached Oversold Weakness 6.20%
Wide Bands Range Expansion 6.20%
Older End-of-Day Signals for CADL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 1 hour ago
Rose Above 10 DMA about 1 hour ago
Up 2% about 1 hour ago
Up 1% about 1 hour ago
Fell Below Previous Day's Low about 2 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Candel Therapeutics, Inc. Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Drugs Immunotherapy Surgery Tumor Cancer Immunotherapy Radiation Chemotherapy Pancreatic Cancer Metastases

Is CADL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.78
52 Week Low 5.51
Average Volume 45,156
200-Day Moving Average 0.00
50-Day Moving Average 8.68
20-Day Moving Average 7.26
10-Day Moving Average 6.82
Average True Range 0.69
ADX 32.45
+DI 11.06
-DI 24.11
Chandelier Exit (Long, 3 ATRs) 6.62
Chandelier Exit (Short, 3 ATRs) 8.16
Upper Bollinger Bands 8.43
Lower Bollinger Band 6.08
Percent B (%b) 0.26
BandWidth 32.37
MACD Line -0.57
MACD Signal Line -0.56
MACD Histogram -0.0082
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.37
Resistance 3 (R3) 7.39 7.17 7.26
Resistance 2 (R2) 7.17 7.00 7.17 7.22
Resistance 1 (R1) 6.93 6.89 7.05 6.91 7.18
Pivot Point 6.71 6.71 6.78 6.71 6.71
Support 1 (S1) 6.47 6.54 6.59 6.45 6.18
Support 2 (S2) 6.25 6.43 6.25 6.14
Support 3 (S3) 6.01 6.25 6.11
Support 4 (S4) 5.99